FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149185444> ?p ?o ?g. }

• W2149185444 abstract "Induction of potent long lasting effector T cell responses against liver stage malaria antigens strongly correlates with protection from malaria. While Adenovirus serotype 5 (Ad5) based malaria vaccine platforms have the ability to induce potent effector T cell responses against transgenes, high rates of pre-existing Ad5 immunity in malaria endemic regions has prompted study of alternative Ad serotype based malaria vaccines as replacements for Ad5 based malaria vaccines. The research described in this article examines the utility of alternative serotype adenovirus serotype 4 (Ad4) expressing a sporozoite surface protein (circumsporozoite protein (CSP)) (Ad4-CSP) to induce immune responses against CSP. The immunogenicity of Ad4-CSP was also tested in homologous and heterologous prime boost vaccinations in both Ad5 naïve and Ad5 immune backgrounds as compared to use of Ad5-CSP.In Ad5 naïve animals, use of Ad4-CSP priming vaccinations followed by boosting with Ad5-CSP (Ad4-CSP/Ad5-CSP) maximally increased the numbers of CSP specific cytokine secreting cytotoxic T cells relative to repeated use of Ad5-CSP. The Ad4-CSP/Ad5-CSP regimen also induced equivalent levels of CSP specific cell killing as did homologous prime-boost vaccinations with Ad5-CSP, despite stimulating lower numbers of CSP specific cytotoxic T cells. Priming with Ad4-CSP followed by a homologous boost resulted in significantly less CSP specific humoral responses than any other vaccination regimen tested in Ad naïve animals. In Ad5 immune animals, addition of Ad4-CSP in homologous or heterologous prime boost resulted in inductions of higher CSP specific responses than animals repeatedly vaccinated with Ad5-CSP alone. However, the observed responses were well below those observed in similarly treated Ad naïve mice.While the Ad4-CSP/Ad5-CSP and Ad5-CSP/Ad5-CSP vaccination regimens resulted in equivalent CSP specific killing in Ad naïve animals, Ad4-CSP/Ad5-CSP achieved this result with a lower percentage of CSP specific CD8+ T cells and a higher number of IFNγ secreting cells, suggesting that the Ad4-CSP/Ad5-CSP vaccination regimen elicits more efficient cytotoxic T cells. In Ad5 immune animals use of Ad4-CSP improved CSP specific immune responses as compared to repeated use of Ad5-CSP, but could not achieve the levels of immunogenicity observed when the same vaccine regimens were used in Ad naïve animals. These data indicate the existence of some level of immunological cross-reactivity between these two adenovirus subgroups. Based on these results, it is suggested that future studies should undertake similarly stringent analyses of alternative Ad serotypes to establish their effectiveness as replacements for Ad5." @default.
• W2149185444 created "2016-06-24" @default.
• W2149185444 creator A5004667791 @default.
• W2149185444 creator A5016155646 @default.
• W2149185444 creator A5047151480 @default.
• W2149185444 creator A5072833522 @default.
• W2149185444 creator A5083266436 @default.
• W2149185444 creator A5089014771 @default.
• W2149185444 date "2012-06-21" @default.
• W2149185444 modified "2023-10-15" @default.
• W2149185444 title "Immunogenicity when utilizing adenovirus serotype 4 and 5 vaccines expressing circumsporozoite protein in naïve and Adenovirus (Ad5) immune mice" @default.
• W2149185444 cites W1933993196 @default.
• W2149185444 cites W1963973005 @default.
• W2149185444 cites W1988731714 @default.
• W2149185444 cites W1991457992 @default.
• W2149185444 cites W1994127090 @default.
• W2149185444 cites W1994985314 @default.
• W2149185444 cites W1999768026 @default.
• W2149185444 cites W2019001893 @default.
• W2149185444 cites W2034106065 @default.
• W2149185444 cites W2049580315 @default.
• W2149185444 cites W2056718461 @default.
• W2149185444 cites W2062888678 @default.
• W2149185444 cites W2066763944 @default.
• W2149185444 cites W2070457810 @default.
• W2149185444 cites W2073658373 @default.
• W2149185444 cites W2083854857 @default.
• W2149185444 cites W2087670178 @default.
• W2149185444 cites W2089608725 @default.
• W2149185444 cites W2097343988 @default.
• W2149185444 cites W2108476551 @default.
• W2149185444 cites W2124892357 @default.
• W2149185444 cites W2125596172 @default.
• W2149185444 cites W2130373733 @default.
• W2149185444 cites W2135756977 @default.
• W2149185444 cites W2142579851 @default.
• W2149185444 cites W2147989744 @default.
• W2149185444 cites W2157427941 @default.
• W2149185444 cites W2157889559 @default.
• W2149185444 cites W2158202876 @default.
• W2149185444 cites W2159448504 @default.
• W2149185444 cites W2162566767 @default.
• W2149185444 cites W2163861382 @default.
• W2149185444 cites W2167619535 @default.
• W2149185444 cites W2167795903 @default.
• W2149185444 cites W2169375105 @default.
• W2149185444 cites W2169962588 @default.
• W2149185444 cites W2170874107 @default.
• W2149185444 cites W2264983055 @default.
• W2149185444 cites W2316528098 @default.
• W2149185444 doi "https://doi.org/10.1186/1475-2875-11-209" @default.
• W2149185444 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3472263" @default.
• W2149185444 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22720732" @default.
• W2149185444 hasPublicationYear "2012" @default.
• W2149185444 type Work @default.
• W2149185444 sameAs 2149185444 @default.
• W2149185444 citedByCount "11" @default.
• W2149185444 countsByYear W21491854442013 @default.
• W2149185444 countsByYear W21491854442014 @default.
• W2149185444 countsByYear W21491854442015 @default.
• W2149185444 countsByYear W21491854442016 @default.
• W2149185444 countsByYear W21491854442017 @default.
• W2149185444 countsByYear W21491854442019 @default.
• W2149185444 countsByYear W21491854442020 @default.
• W2149185444 countsByYear W21491854442022 @default.
• W2149185444 crossrefType "journal-article" @default.
• W2149185444 hasAuthorship W2149185444A5004667791 @default.
• W2149185444 hasAuthorship W2149185444A5016155646 @default.
• W2149185444 hasAuthorship W2149185444A5047151480 @default.
• W2149185444 hasAuthorship W2149185444A5072833522 @default.
• W2149185444 hasAuthorship W2149185444A5083266436 @default.
• W2149185444 hasAuthorship W2149185444A5089014771 @default.
• W2149185444 hasBestOaLocation W21491854441 @default.
• W2149185444 hasConcept C100701293 @default.
• W2149185444 hasConcept C104317684 @default.
• W2149185444 hasConcept C147483822 @default.
• W2149185444 hasConcept C154317977 @default.
• W2149185444 hasConcept C159047783 @default.
• W2149185444 hasConcept C202751555 @default.
• W2149185444 hasConcept C203014093 @default.
• W2149185444 hasConcept C2778048844 @default.
• W2149185444 hasConcept C2778371730 @default.
• W2149185444 hasConcept C2780115692 @default.
• W2149185444 hasConcept C2780868878 @default.
• W2149185444 hasConcept C2781034427 @default.
• W2149185444 hasConcept C2781074509 @default.
• W2149185444 hasConcept C55493867 @default.
• W2149185444 hasConcept C59822182 @default.
• W2149185444 hasConcept C81444415 @default.
• W2149185444 hasConcept C86803240 @default.
• W2149185444 hasConcept C8891405 @default.
• W2149185444 hasConceptScore W2149185444C100701293 @default.
• W2149185444 hasConceptScore W2149185444C104317684 @default.
• W2149185444 hasConceptScore W2149185444C147483822 @default.
• W2149185444 hasConceptScore W2149185444C154317977 @default.
• W2149185444 hasConceptScore W2149185444C159047783 @default.
• W2149185444 hasConceptScore W2149185444C202751555 @default.
• W2149185444 hasConceptScore W2149185444C203014093 @default.
• W2149185444 hasConceptScore W2149185444C2778048844 @default.
• W2149185444 hasConceptScore W2149185444C2778371730 @default.

• next